Diseases & Longevity · File 27

Osteoarthritis. #1 cause of musculoskeletal disability — and it's not just "wear and tear".

Osteoarthritis affects approximately 528 million people worldwide and is the #1 cause of global musculoskeletal disability. Modern reconceptualization describes it as inflammatory disease affecting the entire joint — cartilage, subchondral bone, synovium, ligaments, and periarticular muscle — not just mechanical wear. It's strongly associated with central obesity, sarcopenia, and cardiometabolic cluster. Structured intervention changes the trajectory.

Why OA is not just wear and tear — it's systemic inflammatory disease

Fsteoarthritis was classically taught as "joint wear from use" — simple mechanical model. Modern evidence has completely reconceptualized: it's an inflammatory disease of the entire joint involving cartilage, subchondral bone, synovium, ligaments, and periarticular muscle. There's measurable chronic low-grade inflammation (cytokines, MMPs, complement), subchondral bone remodeling, synovitis, and periarticular muscle atrophy.

This reading changes intervention. Osteoarthritis has causal link with central obesity — not only by mechanical load but by systemic inflammaging and altered adipokines. Has link with sarcopenia — periarticular muscle atrophy accelerates damage. And has link with cardiometabolic cluster — OA patients have higher incidence of HTN, T2D, CV events. That's the longevity view: it's not just joint, it's systemic cluster.

OA is not just wear — it's systemic inflammatory disease with links to cardiometabolic cluster and sarcopenia. That view changes management.
Knee OA · global

The global weight, in numbers

Data come from GBD, OARSI, ACR, and intervention meta-analyses. They confirm the magnitude and the structured intervention opportunity.

  • Global prevalence

    528M · 1ra discapacidad ME

    Approximately 528 million people have OA globally — knee OA alone affects ~365 million. It's the #1 cause of musculoskeletal disability worldwide.
    — GBD 2019 Osteoarthritis

  • Obesity as risk

    ×4-7 riesgo rodilla

    Obesity significantly multiplies knee and hip OA risk. Mechanism is dual — mechanical overload + systemic inflammaging. 5-10% weight loss significantly reduces pain and improves function.
    — Messier et al., Arthritis Rheum 2005

  • Exercise as treatment

    1ra línea OARSI 2019

    Therapeutic exercise (strength + aerobic) is first-line treatment per OARSI 2019 and ACR — reduces pain, improves function, and delays surgery. Comparable to NSAIDs in efficacy, without their adverse effects.
    — Bannuru et al., Osteoarthritis Cartilage 2019

  • Surgery when indicated

    Prótesis con buen pronóstico

    Total knee / hip arthroplasty has very good long-term results in patients with advanced OA not responding to conservative management. Multidisciplinary decision with orthopedics, considering comorbidities and life expectancy.
    — OARSI 2019; AAOS 2024

Chap. 03 · Joint + systemic

The amplified joint-systemic cluster

OA doesn't affect only the joint — its trajectory is strongly linked with sarcopenia, cardiometabolic cluster, depression, and autonomy loss.

  • Periarticular sarcopenia

    Acelera daño

    Periarticular muscle atrophy (quadriceps in knee, glutes in hip) accelerates joint damage and increases fall risk. Specific strength training is indispensable — not optional.
    — Bennell et al., Lancet 2012

  • Cardiometabolic cluster

    Comorbilidad bidireccional

    OA patients have higher incidence of HTN, T2D, and CV events — link through shared inflammaging, pain-induced sedentarism, and concomitant obesity. Integrated management is CV prevention.
    — Veronese et al., Maturitas 2019

  • Depression and chronic pain

    Bidireccional

    Chronic joint pain and depression mutually amplify — affect quality of life, exercise adherence, and functional trajectory. Structured psychosocial approach is integral to management.
    — IASP 2020

  • Autonomy loss

    Discapacidad ADL

    Advanced OA (particularly knee, hip, spine) significantly reduces activities of daily living capacity — walking, climbing stairs, dressing. Its impact on SF-36 PCS is among the most severe documented.
    — Hu et al., BMC Public Health 2024

What we don't offer — and what we do

Wellness Care does not perform orthopedic surgery or joint injections in isolated management of advanced OA. Arthroplasty, intra-articular injections (corticosteroid, hyaluronic acid), advanced therapies, and surgical management of severe OA are orthopedist's competence. What we do: the reading of OA as systemic cluster, addressing the underlying cardiometabolic cluster, prevention of periarticular sarcopenia, and coordination with rheumatology, orthopedics, and physiatry.

We evaluate patients with: knee / hip / spine OA in initial-moderate stages, central obesity with joint overload, periarticular sarcopenia, cardiometabolic cluster amplified by chronic pain, or post-arthroplasty patients wanting to optimize functional trajectory. Intervention integrates structured weight loss, progressive strength + cardio training, inflammaging management, psychosocial approach, and coordination with all relevant specialties.

OA is not just articular — it's systemic cluster. Structured longevity intervention changes trajectory, pain, and autonomy measurably.
How we measure it

How OA is evaluated
at Wellness Care

Systemic cluster — body composition + strength + cardiometabolic cluster + inflammaging. In coordination with rheumatology, orthopedics, and physiatry when indicated.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Functional medicine

Shared root causes — mitochondrial dysfunction, inflammaging, neuroendocrine dysregulation — before organ pathology.

Explore →

Bioregulatory medicine

Autonomic regulation, HRV, stress response. The functional trajectory that precedes clinical diagnosis.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications structuring the modern conversation — GBD 528M, exercise as 1st line, obesity-OA, CV comorbidities.

«La artrosis es la causa #1 de discapacidad musculoesquelética a nivel global — 528 millones de personas afectadas.»
GBD · 2019
GBD 2019 Osteoarthritis Collaborators
Carga global
«El ejercicio terapéutico — fuerza + aeróbico — es primera línea en artrosis según OARSI 2019, con eficacia comparable a AINEs sin sus efectos adversos.»
Osteoarthritis Cartilage · 2019
Bannuru et al., 2019
OARSI guidelines
«Pérdida del 5-10% del peso corporal reduce significativamente el dolor y mejora la función en artrosis de rodilla — el mecanismo es dual: mecánico + inflamatorio.»
Arthritis Rheum · 2005
Messier et al., 2005
Pérdida de peso y rodilla

Frequently asked questions about osteoarthritis

The most recurrent questions about OA — exercise as first line, weight, surgery, biomarkers, and why longevity medicine integrates it as systemic cluster.

01

Is it true that exercise worsens OA?

No — on the contrary.

Structured therapeutic exercise is first line treatment per OARSI 2019, ACR, and EULAR:

· Reduces pain
· Improves function
· Delays progression

Key is appropriate exercise:

· Progressive quadriceps strengthening in knee OA
· Low-impact aerobic — walking, cycling, water
· Mobility exercises

Prolonged rest worsens — accelerates periarticular muscle atrophy and stiffness.

Modern message: "motion is lotion".

02

Does weight loss really help?

Yes, significantly.

Sustained 5-10% body weight loss:

· Reduces pain
· Improves function
· Decreases systemic inflammatory markers in knee OA
· (Messier 2005 Arthritis Rheum)

Dual mechanism:

· Mechanical load reduction
· Systemic inflammaging reduction

In advanced OA with surgical indication, pre-operative weight loss improves post-arthroplasty outcomes.

03

Do joint injections work?

Depends on type:

Intra-articular corticosteroid:

· Short-term effect (weeks-months) on pain
· Repeated use associated with cartilage damage acceleration

Hyaluronic acid:

· Mixed evidence

Regenerative therapies (PRP, stem cells):

· Heterogeneous evidence
· In Colombia, their use requires applicable INVIMA framework and individual medical judgment

Final decision belongs to orthopedist / rheumatologist.

04

When is surgery indicated?

Arthroplasty (total knee / hip prosthesis) is indicated in advanced OA with:

· Refractory pain to comprehensive conservative management (exercise + weight loss + analgesia)
· Severe functional limitation affecting quality of life
· Advanced radiological structural alteration
· Life expectancy justifying intervention

Long-term results are very good in selected patients — but surgery is not trivial:

· Requires preparation ("prehabilitation")
· Management of comorbidities
· Structured post-operative rehabilitation

05

When should I consult?

A structured assessment is worthwhile if:

· Chronic joint pain (>3 months) in knee, hip, or spine
· Overweight or central obesity with joint overload
· Periarticular sarcopenia suspected
· Cardiometabolic cluster amplified by chronic pain
· You've been recommended arthroplasty and want to optimize preparation
· You're post-arthroplasty and want to optimize functional trajectory

The assessment complements rheumatology / orthopedics / physiatry — does not replace them.

It's not just wear

OA is not just wear — it's systemic inflammatory disease with links to cardiometabolic cluster and sarcopenia.

Systemic reading of the articular cluster, structured therapeutic exercise, weight loss, inflammaging management, psychosocial approach, and coordination with rheumatology, orthopedics, and physiatry — that changes real trajectory.

Chronic joint pain or suspected OA?

Book a comprehensive joint and longevity assessment

We evaluate clinical history, body composition (DEXA when applicable), systemic inflammatory profile, muscle strength and sarcopenia, cardiometabolic cluster, and 14 Lancet Commission factors. Does not replace rheumatology, orthopedics, or physiatry — it complements them with the systemic longevity view.

Book joint and longevity assessment